Dr. Rolfo received his medical degree from the National University of Córdoba, Argentina in 1996, and University of Catania, Italy in 2003. He completed his fellowship in Medical Oncology at University of Milan, Italy. He has earned certifications from the European Oncology Board and the Spanish and Belgian Board and spent an internship at MD Anderson Cancer Center in Houston.
From 2012 to March 2018, Dr. Rolfo was the Director of Phase I – Early Clinical Trials Unit and Director of the Clinical Trials Management Program. In addition, senior staff for the Thoracic Oncology Cluster at the Antwerp University Hospital in Belgium. In addition, Professor of the same University.
Dr. Rolfo actively works on drug development and resistance in lung cancer and mesothelioma treatment. His focus of research are liquid biopsies (exosomes and ctDNA) and molecular profiling, he is involved in druggable biomarkers research and immunotherapy in thoracic cancer.
He is Director of the Division of Medical Oncology and Associate Director for early phase clinical trials of the Arthur G. James Cancer Hospital and Solove Research Institute and Ohio State University Comprehensive Cancer Center. Professor of the Departament of Medicine of the Ohio State University College of Medicine.
He worked until August 2024 as Associate Director of Clinical Research of the Center for Thoracic Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York.
Dr. Rolfo is the Deputy Chair of the Educational Committee of the International Association for the Study of Lung Cancer (IASLC), President of The International Society of Liquid Biopsy (ISLB), Member of the Scientific Committee of the European School of Oncology (ESO). He served as Membership Committee of European Society of Medical Oncology (ESMO) . He is a member of the American Society of Clinical Oncology (ASCO) the American Association of Cancer Research (AACR) and other societies.